PL444560A1 - Zastosowanie biomarkera IMA - Google Patents

Zastosowanie biomarkera IMA

Info

Publication number
PL444560A1
PL444560A1 PL444560A PL44456023A PL444560A1 PL 444560 A1 PL444560 A1 PL 444560A1 PL 444560 A PL444560 A PL 444560A PL 44456023 A PL44456023 A PL 44456023A PL 444560 A1 PL444560 A1 PL 444560A1
Authority
PL
Poland
Prior art keywords
ima
biomarker
application
saliva
ischemia
Prior art date
Application number
PL444560A
Other languages
English (en)
Inventor
Mateusz MACIEJCZYK
Julita Szulimowska
Anna ZALEWSKA
Katarzyna Taranta-Janusz
Małgorzata Żendzian-Piotrowska
Original Assignee
Uniwersytet Medyczny W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Białymstoku filed Critical Uniwersytet Medyczny W Białymstoku
Priority to PL444560A priority Critical patent/PL444560A1/pl
Publication of PL444560A1 publication Critical patent/PL444560A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Zgłoszenie wynalazku dotyczy zastosowania stężenia albuminy modyfikowanej niedokrwieniem (IMA) w ślinie jako biomarkera do oceny in vitro chorób nerek, zwłaszcza w populacji pediatrycznej.
PL444560A 2023-04-25 2023-04-25 Zastosowanie biomarkera IMA PL444560A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL444560A PL444560A1 (pl) 2023-04-25 2023-04-25 Zastosowanie biomarkera IMA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444560A PL444560A1 (pl) 2023-04-25 2023-04-25 Zastosowanie biomarkera IMA

Publications (1)

Publication Number Publication Date
PL444560A1 true PL444560A1 (pl) 2024-10-28

Family

ID=93289675

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444560A PL444560A1 (pl) 2023-04-25 2023-04-25 Zastosowanie biomarkera IMA

Country Status (1)

Country Link
PL (1) PL444560A1 (pl)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012469A2 (en) * 2010-07-19 2012-01-26 Otago Innovation Limited Signal biomarkers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012469A2 (en) * 2010-07-19 2012-01-26 Otago Innovation Limited Signal biomarkers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OZKURT, S. ET AL.: "Saudi J Kidney Dis Transpl 2021; 32(4):1006-1012", "ASSESSMENT OF ISCHEMIA MODIFIED ALBUMIN AS A MARKER OF OXIDATIVE STRESS IN CHRONIC KIDNEY DISEASE" *
UZUN, M. ET AL.: "Journal of the American Society of Nephrology, Abstract Supplement, November 2015, vol. 26, abstrakt SA-PO202 str. 671A", "USEFULNESS OF SERUM ISCHEMIA-MODIFIED ALBUMIN LEVELS TO PREDICT DIALYSIS REQIREMENT IN PATIENTS WITH ACUTE RENAL INJURY" *

Similar Documents

Publication Publication Date Title
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2022003212A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
MX2021011715A (es) Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención.
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
CL2019002478A1 (es) Formulación de anticuerpo monoclonal anti-vrs.
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
DK1937721T3 (da) Anti-IL-23 antistoffer
EA201892202A1 (ru) Способы лечения холестатических заболеваний
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
CY1116377T1 (el) Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης
JOP20220204B1 (ar) الأجسام المضادة لـ cd19 البشرية
DK1720909T3 (da) Anti-Abeta antistof
CL2023001052A1 (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
NO20083697L (no) Fremgangsmater for anvendelse av antistoffer mot human IL-22
MX2024005705A (es) Composiciones de liquidos ionicos.
EA200801427A1 (ru) Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека
MA67288A1 (fr) Tubulysines et conjugués tubulysines-protéines
CL2022001185A1 (es) Derivados terapéuticos de interleucina-22
EP4566629A3 (en) Use of low volume plasma exchange for the treatment of alzheimer s disease in early and middle stages
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
MX2022003820A (es) Metodos de tratamiento para modificar la hermodinamica.
MX2022003811A (es) Determinacion no invasiva de glucosa.
MX2022000654A (es) Sistemas fluorescentes para imagenes biologicas y usos de los mismos.
CL2022003288A1 (es) Anticuerpos anti-hbv y métodos de uso
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων